Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Coronary occlusion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    53 result(s) found for: Coronary occlusion. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-000915-26 Sponsor Protocol Number: CMMo-OCC-2012 Start Date*: 2013-09-17
    Sponsor Name:FUNDACIÓN PROGRESO Y SALUD
    Full Title: Clinical Trial Phase III single-center, open-label efficacy of intracoronary infusion of bone marrow mononuclear cells in patients with occlusion Autologous chronic coronary revascularization and v...
    Medical condition: Chronic coronary occlusion
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011086 Coronary artery occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2013-002675-17 Sponsor Protocol Number: TIGER-BVS Start Date*: 2014-05-30
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization
    Medical condition: Chronic total coronary occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004392-23 Sponsor Protocol Number: T189/2016 Start Date*: 2018-02-08
    Sponsor Name:Turku University Hospital
    Full Title: 68Ga-NODAGA-RGD cardiac PET in patients with acute myocardial infarction or chronic total coronary occlusion
    Medical condition: Acute or chronic coronary artery occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2016-002288-32 Sponsor Protocol Number: ESR-14-10310 Start Date*: 2016-11-14
    Sponsor Name:Greek Corporation of Invasive Cardiology
    Full Title: Ticagrelor Potentiation of Remote Ischemic Preconditioning: The Ticagrelor in Remote Ischemic Preconditioning (TRIP) study
    Medical condition: Patient with NSTE-ACS referred for coronary angiography
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002343-30 Sponsor Protocol Number: NEWTON-CABG Start Date*: 2021-09-21
    Sponsor Name:Unity Health Toronto, at its St. Michael’s site
    Full Title: A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG)
    Medical condition: Patency of graft after coronary bypass graft surgery in patients with hyprelipidaemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10011079 Coronary artery disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001452-42 Sponsor Protocol Number: HCB.2021.1309 Start Date*: 2023-01-12
    Sponsor Name:HOSPITAL CLINIC BARCELONA
    Full Title: EVALUATION OF PATIENTS WITH TOTAL CORONARY OCCLUSIONS WITH MULTIMODALITY IMAGE
    Medical condition: Coronary artery chronic total occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002483-11 Sponsor Protocol Number: 18HH4626 Start Date*: 2019-05-15
    Sponsor Name:Imperial College London
    Full Title: CHOlesterol Reduction with Evolocumab and coronAry microvascuLar function: The CHORAL Flow Study
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10005422 Blood cholesterol PT
    21.1 10022891 - Investigations 10002434 Angiogram coronary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-007142-36 Sponsor Protocol Number: CHPAU 2007/01 Start Date*: 2008-05-07
    Sponsor Name:CH Pau
    Full Title: Evaluation des traitements anticoagulants lors d'angioplasties coronaires transcutanées non urgentes.
    Medical condition: Maladie coronaire athéromateuse nécessitant la réalisation d'une angioplastie coronaire transcutanée non urgente.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011082 Coronary artery disorders HLGT
    9.1 10003600 Atheroma coronary artery LLT
    9.1 10011085 Ischaemic coronary artery disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002142-50 Sponsor Protocol Number: POPCABG03 Start Date*: 2019-04-09
    Sponsor Name:St. Antonius Hospital
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery.
    Medical condition: Coronary artery bypass grafting surgery with the use of one or more saphenous vein grafts.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005575-96 Sponsor Protocol Number: LPL100601 Start Date*: 2008-11-26
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)
    Medical condition: chronic Coronary Heart Disease (cCHD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) HU (Completed) SE (Completed) DE (Completed) GB (Completed) SK (Completed) FR (Completed) DK (Completed) EE (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-000238-16 Sponsor Protocol Number: APD791-202 Start Date*: 2021-05-07
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutane...
    Medical condition: Microvascular Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004866 10079682 Microvascular occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004825-14 Sponsor Protocol Number: D1680C00016 Start Date*: 2016-05-04
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin, Saxagliptin Combined with Dapagliflozin, and Sitagliptin in Pat...
    Medical condition: Patients with type 2 diabetes mellitus and heart failure
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) HU (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2014-004649-28 Sponsor Protocol Number: CTO-201 Start Date*: 2015-10-09
    Sponsor Name:Matrizyme Pharma Corporation
    Full Title: A 2-stage study to evaluate single doses of MZ-004 at different dose levels in patients with chronic total occlusions. STAGE 1: Open label Training Stage. STAGE 2: Double-blind, randomized, Pla...
    Medical condition: The use of MZ-004 to facilitate percutaneous coronary intervention in symptomatic patients with a chronic total occlusion who are indicated for revascularization
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003638-17 Sponsor Protocol Number: HEMOPURE II and/or COR-002 Start Date*: 2005-10-28
    Sponsor Name:Biopure Corporation
    Full Title: This is a phase II, open-label study in the catheterization laboratory setting to challenge the concept that HBOC-201 ® administration might improve myocardial ‘oxygenation’ and myocardial function...
    Medical condition: Treatment of several ischemic conditions, such as acute coronary syndromes (ACS)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005491-27 Sponsor Protocol Number: U-08-002 Start Date*: 2008-11-26
    Sponsor Name:UCR Uppsala Clinical Research Center
    Full Title: TAILORING OF PLATELET INHIBITION TO AVOID STENT THROMBOSIS TOPAS-1 A Pharmacodynamic Phase II Study of Clopidogrel P2Y12 Platelet Inhibition
    Medical condition: Previous patients in the TABR study treated with Plavix 75 mg/day and patients with stent thrombosis within 6 months or myocardial infarction within 6 month after stenting. For the control group no...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063933 Coronary stent thrombosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020497-41 Sponsor Protocol Number: ANG.AMI-IC001 Start Date*: 2013-02-13
    Sponsor Name:Mesoblast, Inc.
    Full Title: A prospective, double blind, randomized, placebo-controlled clinical trial of intracoronary infusion of immunoselected, bone marrow-derived Stro3 mesenchymal precursor cells (MPC) in the treatment ...
    Medical condition: ST-elevation myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DK (Completed) SE (Completed) CZ (Completed) AT (Prematurely Ended) PL (Completed) IT (Prematurely Ended) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002876-26 Sponsor Protocol Number: 2017-002876-26 Start Date*: 2018-10-19
    Sponsor Name:South Tees Hospitals NHS Foundation Trust
    Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC)
    Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10011968 Decreased immune responsiveness PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002518-11 Sponsor Protocol Number: 8835-004 Start Date*: 2014-01-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001824-32 Sponsor Protocol Number: 116174 Start Date*: 2015-03-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004901-27 Sponsor Protocol Number: HA007 Start Date*: 2006-05-24
    Sponsor Name:Nuvelo
    Full Title: A Phase 3, Multicenter, Multi-national, Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects with Acute Peripheral Arterial Occlusion (N...
    Medical condition: Acute Peripheral Arterial Occlusion (acute PAO) is to peripheral vascular disease what acute coronary syndromes are to atherosclerotic heart disease and what stroke is to atherosclerotic cerebrovas...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) DK (Completed) HU (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:39:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA